A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Mepolizumab Administered Subcutaneously in Subjects With Moderate to Severe Atopic Dermatitis
Principal Investigator
Vincent C. HoOverview
Study Start/End
Apr 27, 2017 to Dec 31, 2018Locations
Diamond Health Care Centre, Vancouver General Hospital
Name/Title
Jaspal Mor, Study CoordinatorPhone
604-875-5296Email Address
jaspal.mor@ubc.caPurpose of Study
This is a multicenter, randomized, double-blind, placebo-controlled, 2-arm, parallel-group study that will investigate the efficacy and safety of mepolizumab SC in adolescent and adult subjects with moderate to severe AD.
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.